Use of irdenafil or its salt in the preparation of a medicament for preventing or treating ischemic brain injury

High-solubility irdenafil phosphate and tartrate salts address the limitations of current treatments for cerebral ischemia by enabling rapid, safe, and effective administration, improving treatment outcomes for patients with acute conditions.

JP2024543696AActive Publication Date: 2024-11-21ZHENAO JINYINHUA PHARM
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
JP2024535783
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-14
Filing Date
2022-11-30
Publication Date
2024-11-21
Estimated Expiration
2042-11-30

AI Technical Summary

Technical Problem

Current treatments for cerebral ischemia, such as t-PA, Edaravone, and Butylbenzene peptide, are limited in efficacy and safety, and oral administration of irdenafil citrate tablets face issues with slow dissolution, long onset time, and difficulty in administration to patients with swallowing difficulties, leading to low blood drug concentration and large volume injections.

Method used

Development of high-solubility irdenafil phosphate and tartrate salts, which can be administered as injections or oral solutions, providing rapid peak blood concentration and avoiding large volume doses, suitable for patients with acute conditions or swallowing dysfunction.

Benefits of technology

The high-solubility salts enable rapid intravenous administration in small volumes, reducing side effects and improving treatment efficacy for cerebral ischemia by increasing blood drug concentration quickly and safely.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543696000001_ABST
    Figure 2024543696000001_ABST
Patent Text Reader

Abstract

The present invention relates to the use of the compound 1-[4-ethoxy-3-[5-(6,7-dihydro-1-methyl-7-oxy-3-n-propyl-1H-pyrazolo[4,3-d]pyrimidine)]benzenesulfonyl]-3,5-dimethylpiperazine, in particular the use of the compound in the preparation of a drug for the prevention and treatment of diseases caused by cerebral ischemia, in particular ischemic cranial nerve damage and necrosis.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the pharmaceutical field, in particular to the use of the compound 1-[4-ethoxy-3-[5-(6,7-dihydro-1-methyl-7-oxy-3-n-propyl-1H-pyrazolo[4,3-d]pyrimidine)]benzenesulfonyl]-3,5-dimethylpiperazine, in particular to the use of the compound in the preparation of a drug for the prevention and treatment of diseases caused by cerebral ischemia, in particular to the use of the compound in the treatment of ischemic cranial nerve damage and necrosis. [Background technology]

[0002] To date, drugs that have been officially approved clinically for the treatment of diseases caused by cerebral ischemia are very limited. t-PA is the first and only thrombolytic drug approved by the US FDA to date for the treatment of acute cerebral ischemia. It was approved for sale in 1987, but this drug is only effective within 3 hours of onset. Beyond this time window, its effect is unclear and may result in higher incidence of bleeding. Edaravone, approved for sale in Japan, protects brain cells by scavenging oxygen free radicals and inhibiting lipid peroxidation. This product has been reported to have significant adverse reactions and cause severe death. Butylbenzene peptide, approved for sale in China in 2004, can only be used for acute cerebral ischemia. The drugs mentioned above are only used for acute cerebral ischemia and have limited therapeutic effects.

[0003] The compound involved in the present invention is disclosed in Patent No. CN1127506C, and its use in the treatment of erectile dysfunction is also disclosed. Up to now, there has been no report on the prevention and treatment of cerebral ischemia-related diseases. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] CN1127506C Summary of the Invention [Problem to be solved by the invention]

[0005] At present, the marketed product of irdenafil citrate tablets is a tablet. However, oral administration of tablets has the disadvantages of slow disintegration and dissolution process, slow time to reach peak blood drug concentration, slow onset of effect, and difficult administration to patients with serious illnesses (e.g., stroke, coma, or unable to eat). Therefore, it is necessary to develop injections and oral liquids of irdenafil salts to address its shortcomings in clinical use. However, the solubility of irdenafil citrate in water at room temperature is only about 2 mg / ml. When irdenafil citrate is used as an injection in water, the concentration of the dose is low, the total volume of the dose is large, and it is difficult to reconstitute. This limits the rate at which the blood drug concentration of irdenafil can increase in vivo and the method of administration of irdenafil injections, for example, limited to intravenous infusion or large volume injection.

[0006] In the prior art, no injection or oral liquid formulation of iledenafil has been developed, or no high-concentration drug composition for injection or oral liquid has been developed.The high-concentration injection of iledenafil can be administered directly and rapidly, reach peak blood concentration in the body, produce effect quickly, and avoid large volume and long-term administration.The injection and oral liquid of iledenafil have important medical value for patients with acute, severe or swallowing dysfunction (such as stroke, acute thrombosis, confusion, cannot eat, etc.). [Means for solving the problem]

[0007] The present invention provides a compound of formula (I), a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition comprising same, for use in the preparation of a medicament for the treatment or prevention of a human disease caused by cerebral ischemia.

[0008] [ka]

[0009] The compounds of formula (I) have cis- or trans-isomers at the 3,5-dimethyl of the piperazine ring, and the structures of the cis- and trans-isomers are as follows:

[0010] [ka]

[0011] The compound of formula (I) having the cis-structure is airdenafil, whose chemical name is 1-[3-(6,7-dihydro-1-methyl-7-oxy-3-n-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxybenzenesulfonyl]-3,5-dimethylpiperazine.

[0012] In one embodiment, the present invention provides the use of a pharma- ceutically acceptable salt or pharmaceutical composition comprising irdenafil in the preparation of a medicament for the treatment or prevention of a human disease caused by cerebral ischemia.

[0013] In one embodiment, the present invention provides a pharma- ceutically acceptable salt or a pharmaceutical composition thereof for the preparation of a medicament for the treatment or prevention of human focal ischemic cerebral infarction, human ischemic stroke, human focal ischemic memory impairment, and senile dementia, energy metabolic depletion due to human global cerebral ischemia, or cerebral ischemic neurological symptoms caused by human brain trauma.

[0014] In one embodiment, the pharma- ceutically acceptable salts of irdenafil of the present invention include citrate, sulfate, hydrochloride, phosphate, tartrate or hemi-tartrate, nicotinate, lactate, gluconate, maleate or aspartate, preferably citrate, sulfate, hydrochloride, phosphate, tartrate or hemi-tartrate.

[0015] In one embodiment, the airdenafil tartrate or hemi-tartrate used in the present invention is D-tartrate or hemi-D-tartrate, L-tartrate or hemi-L-tartrate, DL-tartrate or hemi-DL-tartrate, meso-tartrate or hemi-meso-tartrate, preferably airdenafil D-tartrate or hemi-D-tartrate, or airdenafil L-tartrate or hemi-L-tartrate.

[0016] As an illustrative example in the present invention, the half L-tartrate salt (2:1) of 1-[4-ethoxy-3-[5-(6,7-dihydro-1-methyl-7-oxy-3-n-propyl-1H-pyrazolo[4,3-d]pyrimidine)]benzenesulfonyl]-cis-3,5-dimethylpiperazine (airdenafil) is as follows:

[0017] [ka]

[0018] The L-tartrate salt of 1-[4-ethoxy-3-[5-(6,7-dihydro-1-methyl-7-oxy-3-n-propyl-1H-pyrazolo[4,3-d]pyrimidine)]benzenesulfonyl]-cis-3,5-dimethylpiperazine (airdenafil) (1:1) has the following structure:

[0019] [ka]

[0020] The pharmaceutical composition comprising either irdenafil or its pharmaceutically acceptable salt in the present invention may be various drug formulations in the art, such as, but not limited to, oral formulations, suppositories, topical formulations, injections, or compound formulations. The drug may comprise irdenafil or its pharmaceutically acceptable salts, or a pharmaceutical composition comprising any one of them and a pharmaceutically acceptable carrier. The preferred effective dosage range for humans is 0.1-20 mg / kg / day, administered once or multiple times per day. Preferably, the oral dosage for humans is 0.2 mg / kg / day-10 mg / kg / day, and the injection dosage for humans is 0.1 mg / kg / day-5 mg / kg / day. As an illustrative example, the dosage for oral administration may be 0.25 mg / kg / day, 1.0 mg / kg / day, or 2.0 mg / kg / day. Dosages for parenteral administration can be 0.2 mg / kg / day, 0.5 mg / kg / day, or 1.0 mg / kg / day.

[0021] In one embodiment of the present invention, the oral preparation includes tablets, granules, capsules or oral liquid, and the injectable preparation includes injection liquid and freeze-dried powder.In one embodiment, the pharmaceutical composition comprising irdenafil or its pharmaceutically acceptable salt according to the present invention is an oral or injectable preparation, preferably tablets, oral liquid or injection liquid.

[0022] In one embodiment of the use of the present invention, the pharma- ceutically acceptable salt of the airdenafil compound is airdenafil citrate.

[0023] In the use of the present invention, as one embodiment, when the drug combination is in tablet form, it may contain ayldenafil citrate, microcrystalline cellulose, anhydrous calcium hydrogen phosphate, cross-linked sodium carboxymethylcellulose, and magnesium stearate, preferably containing 420 g of ayldenafil citrate, a suitable amount of microcrystalline cellulose, a suitable amount of anhydrous calcium hydrogen phosphate, a suitable amount of cross-linked sodium carboxymethylcellulose, and a suitable amount of magnesium stearate.

[0024] The present invention also provides a pharma- ceutically acceptable salt of airdenafil, which is airdenafil phosphate or airdenafil tartrate.

[0025] In one embodiment, the irdenafil tartrate used in the present invention is D-tartrate, L-tartrate, DL-tartrate, or meso-tartrate, preferably D-tartrate or L-tartrate.

[0026] In order to solve the problem of solubility of iledenafil, the present inventor accidentally discovered in the experiment that iledenafil can be made into phosphate or tartrate, which can greatly increase the solubility. The solubility of iledenafil phosphate in water at room temperature reaches nearly 50mg / ml, and the pH value of the aqueous solution is 5-6, which is close to neutral, and the solubility of iledenafil L-tartrate in water at room temperature is about 50mg / ml, while the solubility of iledenafil gluconate in water at room temperature is actually less than 0.2mg / ml. That is, the solubility of iledenafil L-tartrate and phosphate in water at room temperature is more than 200 times higher than the solubility of iledenafil gluconate. Moreover, the dissolution of iledenafil phosphate and L-tartrate in water is very fast, and the aqueous solution is very stable. After 30 minutes of high-temperature and high-pressure sterilization at 121℃, no impurities were produced. Thus, the solubility problem of high concentration injectable and oral solution formulations of aldenafil has been unexpectedly solved.

[0027] The present invention, on the other hand, provides high solubility and high stability of irdenafil salt in water-irdenafil phosphate and tartrate.Irdenafil and tartaric acid can form salt with 1:1 or 2:1 molar ratio.Tartaric acid can be D-tartaric acid, L-tartaric acid, mesotartaric acid, or DL-tartaric acid.

[0028] On the other hand, the present invention also provides the use of irdenafil phosphate and tartrate in the preparation of irdenafil injection and solution. The solubility of irdenafil phosphate is close to 50mg / ml, and the pH value of the aqueous solution is close to neutral. The solution has good stability and is very suitable for injection use. The solubility of irdenafil tartrate in water at room temperature is greater than 50mg / ml, which is very suitable for the preparation of high-concentration injection and solution of irdenafil. After the preparation of lyophilized powder injection with irdenafil phosphate and tartrate, the reconstitution time of high concentration is very short, and the solution is clear, which cannot be achieved by other salts or other solubilization methods. This is the best choice for preparing lyophilized powder injection of irdenafil.

[0029] Compared with the prior art, the phosphate and tartrate salts of irdenafil provided by the present invention have the following advantageous effects:

[0030] 1. The irdenafil phosphate and tartrate of the present invention can be easily dissolved in water at room temperature and dissolve quickly, and their solubility is surprisingly increased by more than 200 times compared with other salts such as gluconate, therefore, it can achieve rapid intravenous administration of irdenafil injection in small volume, greatly improving the rate at which blood drug concentration increases and shortening the time for drug onset.They are particularly suitable for patients who need rapid administration (such as stroke, acute embolism, etc.) and patients with dysphagia.

[0031] 2. The irdenafil phosphate and tartrate of the present invention have high solubility in water, providing the possibility for the preparation of high-concentration injections.This can achieve rapid intravenous administration in small volume, avoid long-term or multiple injections in large volume, and reduce the side effects caused by large volume or multiple injections, such as the burden on the body caused by high volume, and the toxicity caused by the injection of osmotic agents such as excess sodium chloride and glucose.

[0032] 3. The irdenafil phosphate and tartrate of the present invention have good solubility, low degradation impurities, and fast reconstitution speed when used to prepare lyophilized powder needles, and there is no precipitation of the drug at high concentration.

[0033] 4. The synthesis process for the isardenafil phosphate and tartrate of the present invention is simple, and the yield of the salt is nearly 100%. The process is stable, has good reproducibility, is easy to operate, has strong controllability, and is suitable for industrial production.

[0034] The present invention also provides a process for preparing airdenafil or a pharma- ceutically acceptable salt thereof, comprising cyclization of 4-[2-ethoxy-5-(cis-3,5-dimethylpiperazine-1-sulfonyl)benzamido]-1-methyl-3-n-propylpyrazole-5-formamide to synthesize airdenafil, wherein the base catalyst is sodium tert-butoxide. [Brief description of the drawings]

[0035] [Figure 1] FIG. 2 shows HNMR of irdenafil L-tartrate in Example 3. [Diagram 2] FIG. 13 shows blank water in Example 18. [Diagram 3] FIG. 17 shows citric acid in Example 18. [Figure 4] FIG. 1 shows the aidenafil citrate salt in Example 18. [Diagram 5] FIG. 17 shows the irdenafil citrate sample after 1.5 hours of sterilization in Example 18. [Figure 6] FIG. 1 shows the ayrdenafil phosphate salt in Example 18. [Figure 7] FIG. 17 shows the ayrdenafil phosphate sample after 1.5 hours of sterilization in Example 18. [Figure 8] FIG. 1 shows L-tartaric acid in Example 18. [Figure 9]FIG. 1 shows the results of the preparation of irdenafil L-tartrate in Example 18. [Figure 10] FIG. 17 shows the sample of irdenafil L-tartrate after 1.5 hours of sterilization in Example 18. [Figure 11] FIG. 13 shows the results of monitoring rat body weight in Example 21. [Figure 12] FIG. 13 shows a typical legend for ADLS1026 treatment of cerebral infarction area for acute ischemic stroke in rats in Example 24, including A: model control group, B: low dose group, C: medium dose group, and D: high dose group. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0036] The present invention will be further illustrated by the following examples. The examples of the present invention are not intended to limit the present invention, and it should be understood that any simple improvement made to the present invention under the premise that the present invention is within the scope of protection claimed by the present invention. EXAMPLES

[0037] Example 1: Preparation of Aildenafil and Aildenafil Citrate Step 1: Preparation of 5-chlorosulfonyl-2-ethoxybenzoic acid 23 ml of sulfoxide chloride was added to a 250 ml four-necked bottle under nitrogen protection at a freezer bath temperature of -5°C, and 81 ml of chlorosulfonyl chloride was added dropwise. 2-ethoxybenzoic acid was dissolved in a warm water bath to form a solution, and 52.5 g of 2-ethoxybenzoic acid was weighed and added dropwise while releasing heat. After the 2-ethoxybenzoic acid was added, it was stirred and allowed to react overnight. The reaction solution was brown and viscous. The reaction solution was removed and placed at room temperature.

[0038] A 1000ml three-necked bottle was placed in the frozen solution, 750ml water was added, and frozen to 3°C. The reaction solution was added dropwise at a temperature below 10°C. After the reaction solution was added dropwise, a white solid precipitated. At the beginning, the solid was slightly attached to the wall, and then it could be stirred and dispersed. After the addition, stirring was carried out at room temperature for at least 1 hour. The solution was filtered, washed with 50ml x 3 water at room temperature, and dried by suction to obtain a white crystalline solid with a wet weight of 68.8g. The white crystals were dried at room temperature overnight. The melting point was measured to be 113-116°C.

[0039] Step 2: Preparation of 2-ethoxy-5-(cis-3,5-dimethylpiperazine-1-sulfonyl)benzoic acid (III).

[0040] [ka]

[0041] 170 ml of water was added to a 1000 ml three-necked bottle and cooled to 5° C., and 60 g wet weight of the product 5-chlorosulfonyl-2-ethoxybenzoic acid obtained in step 1 was added and dispersed. cis-2,6-dimethylpiperazine was added in one portion under stirring to release heat from the reaction. The reaction temperature was controlled below 10° C. After addition, freezing was stopped and the solution was stirred overnight and the pH was measured to be 10. The solution was stirred for 2 hours for crystallization, filtered, washed three times with ice water, and dried by suction to obtain 95.0 g wet white product. The white product was air-dried at 50° C., sampled, and tested. The pH of the filtrate was adjusted to 6-7 with 85% phosphoric acid to precipitate the crystals. After adjustment, the solution was stirred for 1 hour, filtered, and washed with water to obtain about 30 g wet weight of white crystals. The white crystals were air-dried at 50°C to obtain a total of 67.0g. The mixture was crushed, 200ml of acetone was added, refluxed for 1 hour, almost completely dissolved, cooled to room temperature, left for 1 hour, filtered, rinsed with 50ml x 3 of acetone, dried by suction, and air-dried at 50°C for 2 hours to obtain 67.2g of almost white crystals. The melting point was 258.1-258.7°C.

[0042] Step 3: Preparation of 2-ethoxy-5-(cis-3,5-dimethylpiperazine-1-sulfonyl)benzoyl chloride

[0043] [ka]

[0044] 67.2g of the product obtained in step 2 was added to a 500ml one-mouth bottle, 150ml of sulfur chloride was added, dissolved and effervescent, heated to 50°C, dissolved to a clear solution, heated and refluxed for 3 hours. The released hydrogen chloride gas was absorbed with alkaline water, spin-dried, 300ml of ethyl acetate was added, shaken to form a homogeneous solution, and yellow crystals were precipitated rapidly. The yellow crystals were left overnight for crystallization, filtered, rinsed with ethyl acetate, dried by suction and at room temperature for 1 hour, and then air-dried at 50°C for 2 hours to obtain 65.0g of yellow crystalline product.

[0045] Step 4: Preparation of 4-[2-ethoxy-5-(cis-3,5-dimethylpiperazine-1-sulfonyl)benzamido]-1-methyl-3-n-propylpyrazole-5-formamide

[0046] [ka]

[0047] 1.0g DMPA, 30.0g pyrazoleformamide, and 320ml dichloromethane were added to a 1000ml three-necked bottle, dissolved and clarified, 34.0g triethylamine was added, and cooled to 0°C under stirring. The temperature of the reaction solution was -3°C. A total of 63.5g of the product obtained in step 3 was added in one batch, and heat was released. The temperature of the reaction solution was controlled below 5°C. After addition, freezing was stopped, the temperature was raised to room temperature, and the reaction was stirred for more than 2 hours. The solution was evaporated under reduced pressure to dryness, 300ml water was added, stirred to crystallize, and filtered to give a red-brown filtrate and a yellow product. The product was washed with water 100ml x 3 times and ethyl acetate 100ml x 3 times, the red color was washed off with ethyl acetate, and an essentially colorless filtrate was obtained, which was dried by suction to give 88.6g wet weight of loose off-white crystals. The crystals were first air-dried at room temperature and then blow-dried at 50°C for 3 hours to give 69.0 g with a measured melting point of 194.3-195.1°C.

[0048] 69g of the crude product obtained above was added to a 1000ml one-mouth bottle, 560ml water and 280ml methanol were added, heated and refluxed. It was found that it could not be completely dissolved. 100ml methanol was added, refluxed to dissolve and clear, the white matter was filtered while hot, and white crystals precipitated rapidly from the filtrate. The filtrate was left for 5 hours, filtered, washed with 150ml of 1:2 ratio methanol:water, dried by suction, and air-dried at 50°C to constant mass, yielding 60.0g. Melting point was measured at 199.4-199.9°C.

[0049] Detection method: Use octadecylsilane-bonded silica gel as the filler, 0.05 mol / L triethylamine phosphate (7 ml of triethylamine is diluted to 1000 ml with water and the pH is adjusted to 3.0 with phosphoric acid)-methanol acetonitrile (58:25:17) as the mobile phase, and a detection wavelength of 290 nm.

[0050] Step 5: Preparation of cyclization of 5-[2-ethoxy-5-(cis-3,5-dimethylpiperazine-1-sulfonyl)phenyl]-1-methyl-3-n-propyl-7,6-dihydro-1H-pyrazolo[4,3-d]pyrimidine-7-ketone

[0051] [ka]

[0052] 300ml of tert-butanol was added to a 1000ml dry one-mouth bottle, and 3.0g of metallic sodium was added in one batch under magnetic stirring at room temperature. After metallic sodium was added, the bottle was heated to 70°C and stirred by magnetic stirring until metallic sodium disappeared (sodium tert-butoxide was generated in situ or commercial sodium tert-butoxide product can be added directly). 57g of the product obtained in step 4 was added in one batch under stirring. After addition, stirring and refluxing were performed for at least 8 hours. The reaction solution was cooled to room temperature, and 500ml of water was added dropwise at room temperature and stirred uniformly. Vacuum evaporation was performed to remove tert-butanol, and the solution was stirred at room temperature for more than 2 hours, filtered, washed with water until neutral, and air-dried at 50°C to obtain 40g of crude product. 1000ml of ethanol was added to the crude product, refluxed to obtain a clear solution, cooled to crystallize. The solution was filtered and the crystals were dried under air at 50° C. to give 35.1 g of airdenafil product.

[0053] Step 6: Preparation of Aildenafil Citrate

[0054] [ka]

[0055] 870 ml of absolute ethanol, 34.8 g of iledenafil, and 17.4 g of citric acid monohydrate were added to a 1000 ml single-mouth bottle and heated and refluxed for 1.5 hours. Heating was stopped. The solution was stirred and naturally cooled to room temperature for crystallization for more than 5 hours. The solution was filtered, and the crystals were rinsed with ethanol, dried by suction, and air-dried at 50°C to constant mass. The product of iledenafil citrate was 47.4 g, which was white crystals with a yield of 97.7%, a melting point of 210.2-211.9°C (melt decomposition), and a purity of more than 99.9%. It was crushed through an 80 mesh sieve to obtain a white powder product. Mass spectrometry [M+H]+ was 489.50.

[0056] Example 2: Preparation of Aildenafil Citrate

[0057] [ka]

[0058] 60ml of absolute ethanol and 2.45g of iledenafil were added to a 250ml single-mouth bottle, heated and refluxed to dissolve and clarify, and a solution containing 1.1g of citric acid monohydrate and 5ml of absolute ethanol was added. Heating was stopped, and the solution was stirred for more than 5 hours and allowed to cool naturally to room temperature for crystallization. The solution was filtered to obtain crystals, which were rinsed with ethanol, dried by suction, and dried by blowing air at 60°C to constant weight to obtain 3.33g of product, which was white crystals with a yield of 97.7%, a melting point of 216.5-217.0°C (melt decomposition), and a purity of 100%.

[0059] Example 3: Preparation of Aildenafil L-tartrate

[0060] [ka]

[0061] 2.45g of iledenafil white crystalline powder was added to a 250ml bottle, 60ml of absolute ethanol was added, and the mixture was heated to reflux for dissolution and clarification. A clear solution of 0.77g of L-tartaric acid and 5ml of absolute ethanol was added to the solution to precipitate the solid. After this, reflux was performed for 30 minutes. The solution was naturally cooled and stirred at room temperature overnight for crystallization. The solution was suction filtered, and the crystals were rinsed twice with 5ml of absolute ethanol and then dried by suction to obtain a white solid. The crystals were air-dried at 60°C to constant mass. The crystals were oven-dried to constant mass to obtain 3.2g of white crystals with a yield of 100% and a melting point of 205.8-207.4°C. The HNMR image is shown in Figure 1.

[0062] Example 4: Preparation of Aildenafil Phosphate

[0063] [ka]

[0064] 4.89g of iledenafil white crystalline powder was added to a 250ml single-mouth bottle, 120ml of absolute ethanol was added, and the mixture was heated and refluxed to dissolve and clarify, and 1.15g of 85% phosphoric acid was added to obtain a cloudy reaction solution and precipitate a solid. After addition, reflux was performed for 30 minutes. The mixture was naturally cooled to crystallize, and the solution was stirred at room temperature overnight. The solution was suction filtered, and the crystals were rinsed twice with 5ml of absolute ethanol and then dried by suction to obtain a white solid. The white solid was air-dried at 80°C to a constant mass. This was oven-dried to a constant mass to obtain 5.8g of white crystals with a yield of 98.8% and a melting point of 225.3-227.0°C.

[0065] Example 5: Preparation of Aildenafil Maleate

[0066] [ka]

[0067] 2.45g of iledenafil white crystalline powder was added to a 250ml single-mouth bottle, 60ml of absolute ethanol was added, and the mixture was heated and refluxed to dissolve, and 0.59g of maleic acid was added to precipitate the solid. After addition, reflux was performed for 30 minutes. The mixture was naturally cooled to crystallize, and the solution was stirred at room temperature overnight. The solution was filtered by suction, and the crystals were rinsed twice with 5ml of absolute ethanol, and then dried by suction to obtain a white solid. The white solid was dried by blowing air at 60°C to a constant mass. This was dried to a constant mass to obtain 2.8g of white crystals with a yield of 92.4% and a melting point of 221.0-222.3°C.

[0068] Example 6: Preparation of Aildenafil Gluconate

[0069] [ka]

[0070] 1.00g of iledenafil white crystalline powder was added to a 250ml single-mouth bottle, 26ml of absolute ethanol was added, and the mixture was heated and refluxed to dissolve and clarify, and 0.81g of gluconic acid solution (49-53%) was added dropwise. After addition, reflux was performed for 30 minutes. The mixture was naturally cooled to crystallize, and a cloudy solution was obtained due to the precipitation of crystals at about 45°C. The solution was stirred overnight at room temperature. It was suction filtered, rinsed twice with 5ml of absolute ethanol, and then dried by suction to obtain a white solid. It was dried by blowing air at 60°C to constant weight. It was oven-dried to constant weight to obtain 0.6g of white crystals with a yield of 42.8% and a melting point of 195.0-195.8°C.

[0071] Example 7: Preparation of aldenafil lactate

[0072] [ka]

[0073] 2.45g of iledenafil white crystalline powder was added to a 250ml single-mouth bottle, 60ml of absolute ethanol was added, and the mixture was heated and refluxed to dissolve and clarify, and 0.51g of lactic acid was added. After addition, the mixture was dissolved rapidly and refluxed for 30 minutes. Natural cooling was performed to crystallize, which began at 40°C, and the solution was stirred overnight at room temperature, suction filtered, washed twice with 5ml of absolute ethanol, and then dried by suction to obtain a white solid. This was blown dry at 60°C to a constant mass. This was oven-dried to a constant mass to obtain 2.2g of white crystals with a yield of 75.9% and a melting point of 180.6-181.8°C.

[0074] Example 8: Preparation of Ayrdenafil Aspartate

[0075] [ka]

[0076] 1.00g of iledenafil white crystalline powder was added to a 250ml single-mouth bottle, 26ml of absolute ethanol was added, and the mixture was heated and refluxed to dissolve and clarify, and 0.31g of aspartic acid was added. After addition, the mixture was rapidly dissolved and clarified, and refluxed for 30 minutes. The mixture was naturally cooled to crystallize, and the solution was stirred overnight at room temperature, suction filtered, washed twice with 5ml of absolute ethanol, and then dried by suction to obtain a white solid. This was blown dry at 60°C to a constant mass. This was oven-dried to a constant mass to obtain 1.0g of white crystals with a yield of 78.9% and a melting point of 193.1-194.4°C.

[0077] Example 9: Preparation of irdenafil nicotinate

[0078] [ka]

[0079] 2.45g of iledenafil white crystalline powder was added to a 250ml single-mouth bottle, 60ml of absolute ethanol was added, and the powder was heated and refluxed to dissolve and clarify, and 0.62g of niacin was added. After addition, the powder was rapidly dissolved and clarified, and refluxed for 30 minutes. The powder was naturally cooled to crystallize, which started at around 45°C, stirred at room temperature overnight, filtered by suction, washed twice with 5ml of absolute ethanol, and then dried by suction to obtain a white solid. The powder was air-dried at 60°C to a constant weight. The powder was oven-dried to a constant weight to obtain 2.8g of white crystals with a yield of 91.5% and a melting point of 204.0°C to 205.0°C.

[0080] Example 10: Preparation of Aildenafil Hydrochloride

[0081] [ka]

[0082] 4.89g of iledenafil white crystalline powder is added to a 250ml single-mouth bottle, 120ml of absolute ethanol is added, and the powder is dissolved and clarified by heating and refluxing, and 1.01g of 36.5% hydrochloric acid is added to precipitate solids, and refluxing is performed for 30 minutes after addition. The powder is naturally cooled to crystallize, and the solution is stirred at room temperature overnight, suction filtered, washed twice with 5ml absolute ethanol, and then dried by suction to obtain a white solid. The powder is blown dry at 60°C to a constant weight. The powder is oven-dried to a constant weight to obtain 5.2g of white crystals with a yield of 99.0% and a melting point of over 250°C.

[0083] Example 11: Preparation of Aildenafil Sulfate

[0084] [ka]

[0085] 4.89g of iledenafil white crystalline powder was added to a 250ml single-mouth bottle, 120ml of absolute ethanol was added, and the mixture was heated and refluxed to dissolve and clarify, 0.52g of concentrated sulfuric acid was added to precipitate a large amount of solid, and reflux was performed for 30 minutes after addition. The mixture was naturally cooled to crystallize, and the solution was stirred at room temperature overnight, suction filtered, washed twice with 5ml of absolute ethanol, and then dried by suction to obtain a white solid. This was air-dried at 60°C to a constant mass. This was oven-dried to a constant mass to obtain 4.4g of white crystals with a yield of 81.8% and a melting point of 236.4-237.8°C.

[0086] Example 12: Preparation of aldenafil D-tartrate

[0087] [ka]

[0088] 1.0g of iledenafil white crystalline powder was added to a 250ml single-mouth bottle, 31ml of absolute ethanol was added, and the mixture was heated and refluxed to dissolve and clarify, and a clear solution containing 0.31g of D-tartaric acid and 5ml of absolute ethanol was added to precipitate the solid, and refluxed for 30 minutes after addition. The solution was naturally cooled to crystallize, stirred overnight at room temperature, filtered by suction, rinsed twice with 5ml of absolute ethanol, and then dried by suction to obtain a white solid. This was blown dry at 60°C to a constant mass. This was oven-dried to a constant mass to obtain 1.0g of white crystals with a melting point of 207.0-208.0°C.

[0089] Example 13: Preparation of Aildenafil DL-tartrate

[0090] [ka]

[0091] 1.0g of iledenafil white crystalline powder was added to a 250ml single-mouth bottle, 31ml of absolute ethanol was added, and the mixture was heated and refluxed to dissolve and clarify, and a clear solution containing 0.31g of DL-tartaric acid and 5ml of absolute ethanol was added to precipitate the solid, and refluxed for 30 minutes after addition. The mixture was naturally cooled to crystallize, and the solution was stirred overnight at room temperature, suction filtered, rinsed twice with 5ml of absolute ethanol, and then dried by suction to obtain a white solid. This was blown dry at 60°C to a constant mass. This was oven-dried to a constant mass to obtain 1.0g of white crystals with a melting point of 197.0-198.0°C.

[0092] Example 14: Preparation of Aildenafil meso-tartrate

[0093] [ka]

[0094] 1.0g of iledenafil white crystalline powder was added to a 250ml single-mouth bottle, 31ml of absolute ethanol was added, and the solution was dissolved and clarified by heating and refluxing, and the clear solution containing 0.31g of mesotartaric acid and 5ml of absolute ethanol was added to precipitate the solid, and refluxing was carried out for 30 minutes after addition.The solution was naturally cooled to crystallize, and stirred at room temperature overnight, suction filtered, rinsed twice with 5ml of absolute ethanol, and then dried by suction to obtain a white solid.The solid was blown dry at 60°C until constant weight.The solid was oven-dried until constant weight to obtain 1.1g of white crystals.

[0095] Example 15: Preparation of aldenafil hemi-L-tartrate

[0096] [ka]

[0097] 2.45g of iledenafil white crystalline powder was added to a 250ml single-mouth bottle, 60ml of absolute ethanol was added, and the mixture was heated and refluxed to dissolve and clarify, and a clear solution containing 0.38g of L-tartaric acid and 5ml of absolute ethanol was added to precipitate the solid, resulting in a cloudy solution, and refluxed for 30 minutes. The solution was naturally cooled to crystallize, stirred overnight at room temperature, suction filtered, rinsed twice with 5ml of absolute ethanol, and then dried by suction to obtain a white solid. This was blown dry at 60°C to a constant mass. This was oven-dried to a constant mass to obtain 2.4g of white crystals with a yield of 85% and a melting point of 210.0-211.5°C.

[0098] Example 16: Preparation of aldenafil L-tartrate

[0099] [ka]

[0100] 1.0g of iledenafil white crystalline powder was added to a 250ml single-mouth bottle, 19ml of 95% ethanol was added, and the mixture was heated and refluxed to dissolve and clarify, and a clear solution containing 0.32g of L-tartaric acid and 5ml of 95% ethanol was added to precipitate the solid in about 5 minutes, resulting in a cloudy solution, and refluxed for 30 minutes. The solution was allowed to crystallize by natural cooling, stirred overnight at room temperature, suction filtered, rinsed twice with 5ml of absolute ethanol, and then dried by suction to obtain a white solid. This was blown dry at 60°C to a constant mass. This was oven-dried to a constant mass to obtain 1.2g of white crystals with a yield of 91.6% and a melting point of 206.0-207.0°C.

[0101] Example 17: Room temperature water solubility of different aldenafil salts The saturation solubility of different aldenafil salts in water was measured at room temperature and the results are as follows:

[0102] [Table 1]

[0103] Experimental results: after salification, all iledenafil salts are white crystals, but the saturation solubility of different salts in water is greatly different, and the difference between the maximum solubility and the minimum solubility is more than 200 times. Among them, L-tartrate can be easily dissolved in water at room temperature with a saturation concentration of about 50mg / ml after dissolution. The saturation concentration of phosphate dissolved in water at room temperature was about 50mg / ml. In contrast, the maximum concentration of other salts after saturation can only reach about 6mg / ml (hydrochloride 6mg / ml). Gluconate, which has a similar structure to tartrate, is almost insoluble in water at room temperature, and its concentration after saturation was less than 0.2mg / ml. The solubility of iledenafil L-tartrate and phosphate in water was very surprising. In addition, iledenafil L-tartrate and phosphate dissolve rapidly in water and dissolve and become clear in 15 seconds by shaking by hand, which is very beneficial for the reconstitution of freeze-dried powder injection. Furthermore, in terms of the yield of salt formation, the yield of irdenafil L-tartrate and phosphate was more than 95%, which basically meets the requirement of atomic economy.

[0104] Example 18: Sterilization stability test for aqueous solutions of Aildenafil citrate, Aildenafil phosphate, and Aildenafil L-tartrate 10mg each of irdenafil L-tartrate, irdenafil phosphate, and irdenafil citrate were added to a 20ml volumetric flask and purified water was added to the volume. They were sterilized in a sterilizer at 121°C for 30 minutes and sampled before and after sterilization. Related substances were measured according to the following method.

[0105] Related substances: Take a sample and dissolve it in the mobile phase to prepare a solution containing 0.5 mg per ml, which was used as the test solution; with a detection wavelength of 290 nm, octadecylsilane-bonded silica gel as filler, and phosphate buffer (800 ml water, add 7 ml triethylamine, adjust pH to 3.0 with phosphoric acid, dilute with water to 1000 ml)-methanolacetonitrile (58:25:17) as mobile phase.

[0106] Experimental results: Aqueous solutions of 0.5 mg / ml of irdenafil L-tartrate, irdenafil phosphate, and irdenafil citrate were sterilized at 121°C for 30 minutes, and no impurities were found. There was no difference in the HPLC images of the solutions before and after sterilization. The HPLC images before and after sterilization are shown in Figures 2-10. The results are shown in the table below.

[0107] Comparison of related substances of different salts at 0.5mg / ml sterilized at 121℃ for 30 minutes

[0108] [Table 2]

[0109] Example 19: pH measurements of different representative aldenafil salts dissolved in water The most water-soluble aledenafil salt was determined: aledenafil tartrate and aledenafil phosphate, and compared with aledenafil citrate. The results are as follows:

[0110] [Table 3]

[0111] Unexpectedly, it has been discovered that the pH of the phosphate salts is close to physiological pH, making them suitable for injectable administration.

[0112] Example 20: Preparation of Irdenafil Citrate Formulation Aildenafil citrate can be made into various preparations including tablets, granules, capsules, sublingual patches, suppositories, topical preparations, oral liquids, injections, etc. A typical oral immediate release tablet can be prepared as follows:

[0113] The formulation for aldenafil citrate tablets is as follows: The formula for 60 mg of aldenafil tablets (calculated by alkali) is as follows (5000 tablets):

[0114] [Table 4]

[0115] The tablet preparation process was as follows:

[0116] Microcrystalline cellulose, irdenafil raw material, anhydrous calcium hydrogen phosphate, and cross-linked sodium carboxymethylcellulose according to the prescribed amount (5000 tablets) were weighed, milled through 80 mesh sieve, and mixed. Pure water was added to the mixed, milled, and sieved material mentioned above, wet granulated, and mixed for 15 minutes to prepare a soft material, and then passed through 16 mesh sieve to granulate. The amount of water was adjusted according to the granulation state. The prepared granules were dried by blowing air in an oven at a temperature of 60°C ± 5°C for 4 hours, and the mass loss during drying was measured. After drying, the mass loss was quantified, and the dried granules were sieved and sized through 10 mesh sieve to obtain granules. After granulation, the mixture was placed in a 3D motion mixer, and a specified amount of magnesium stearate was added and mixed for 100 revolutions. Samples were taken and tested. All the mixed materials were fed into the feeding hole of a tablet press, and tablets were pressed under the control of the feeding height. The tablet mass was adjusted to 360 mg with a hardness of 30-60 N and a friability of less than 0.3%. The difference between the tablet masses was controlled at (±4%).

[0117] Example 21: Comparative study on the repair effect of oral administration of irdenafil citrate and sildenafil citrate on nerve injury in MCAO rats 1. Experimental Drugs Aildenafil Citrate: White powder, solid, with a purity of over 99%. Homemade, batch number 20191127-1. Sildenafil Citrate (USP): White powder, solid, with a purity of more than 99%. Manufacturer AZICO BIOPHORE, India; Batch number: 4002 / 4 / 005 / 20.

[0118] 2. Experimental Animals SD rat, 210-230g.

[0119] 3. Drug Form Irdenafil citrate: Dissolve in pure water to prepare a 2 mg / ml drug solution, refrigerate at 4°C and store for use. Sildenafil citrate: Dissolve in pure water to prepare a 2 mg / ml drug solution, and store in a refrigerator at 4°C before use.

[0120] 4. Route of administration, dosage, and frequency Route of administration: oral gavage; Dosage: 4 mg / kg body weight, twice daily; Dosage frequency: Two oral gavage doses per day, in the morning and evening (administered immediately after modeling).

[0121] 5.Generating the MCAO Model A rat model of middle cerebral artery ischemia / reperfusion (MCAO / R) was created using a suture method.

[0122] 6. Experimental Grouping The experimental rats were randomly divided into 4 groups, with 30 rats in each group, and were labeled as MCAO model group (referred to as model group), sham group, treatment group 1 (ildenafil group), and treatment group 2 (sildenafil group).

[0123] (1) MCAO model group: cerebral ischemia-reperfusion group; (2) Sham group: after surgical exposure of the carotid artery, suturing was performed without ischemia-reperfusion injury; (3) Treatment group 1: MCAO model + alder citrate drug treatment group; (4) Treatment group 2: MCAO model + sildenafil citrate drug treatment group;

[0124] 7. Experimental Metrics Weight monitoring The physical recovery of rats after cerebral infarction treated with different therapeutic agents was indirectly evaluated by monitoring the weight gain of rats in different groups at different times during the experimental process.

[0125] Neuropathy (mNSS) score: Scores were assessed using the mNSS rat neuropathy scoring method. Neuropathy in experimental rats was assessed 14 days after modeling.

[0126] Behavioral experiments: Morris Water Maze Experiment: Testing the learning and memory ability of rats.

[0127] The Morris water maze experiments were performed on six consecutive days each time, with training taking place on the first five days and testing on the sixth day.

[0128] For each test, rats were trained four times a day (once in the first, second, third and fourth quadrants, respectively) for a fixed period of time during the first five days. At the beginning of training, the platform was placed in the first quadrant, and the rat was placed in the pool facing the pool wall from any starting point of the four quadrants on the pool wall. The camera system records the time when the rat found the platform and the swimming path of the rat. The four training sessions required placing the rat in the water from four different starting points. If the rat found the platform or could not find it within 60 seconds, the experimenter guided the rat to the platform and allowed it to rest on the platform for 10 seconds, then proceeded to the next trial.

[0129] The rats were removed from the platform, dried with a soft cloth and returned to their cages, after which the next trial for the rat was performed until the numbered animal had finished swimming, and then the next set of trials was performed.

[0130] The experiment was carried out on the 14th day after administration. The experiment was carried out for 6 consecutive days, the first 5 days being swim training, and the 6th day being testing.

[0131] 8. Experimental Results Weight monitoring

[0132] [Table 5]

[0133] The results of body weight showed that the sham operation group (sham group) had normal body weight gain with only a slight decrease in body weight on the fourth day after surgery. On the fourth day after surgery, the weight loss of the model group and the treatment group was about 1 / 6, showing a significant decrease, indicating that the surgery caused serious damage to the rats. The weight recovery of the treatment group was faster than that of the model group. Statistics show that the distribution of body weight data at different time points in the model group, sham group and two treatment groups has homogeneity of variance. The probability value of T for the body weight of the model group and the sham operation group was 0.005 after T test, showing a significant difference between the two groups. This indicates that the model operation has a very significant effect on the rats. As shown in the data graph, the weight recovery of the iledenafil group (treatment group 1) was faster than that of the sildenafil group (treatment group 2), indicating that iledenafil is more effective in promoting the recovery of ischemic brain injury than the sildenafil group. The data is shown in Figure 11.

[0134] Neuropathy score The neurological impairment and damage scores of the rats after 14 days of treatment using the nMSS neurobehavioral score are shown in the table below.

[0135] [Table 6]

[0136] After 14 days of administration, the recovery of nerve function is better in the group treated with irdenafil than in the group treated with sildenafil, with a highly significant difference (p=0.01).Irdenafil group also shows a highly significant recovery compared with model group (p=0.002).The experimental results are very surprising, showing that irdenafil can promote the recovery of nerve function in ischemic injury rats more effectively than sildenafil, and there is a significant difference.

[0137] Morris water maze experiment results The results of the water maze test on the 14th day showed that the average latency of the sham group was 4.9 seconds, the model group was 32.51 seconds, the iledenafil group (treatment group 1) had an average latency of 8.93 seconds, and the sildenafil group (treatment group 2) had an average latency of 16.88 seconds. The experiment also unexpectedly found that the latency of the iledenafil group was shorter than that of the model group, with a significant difference (P=0.03), but there was no significant difference in the latency between the sildenafil group and the model group (P=0.148), indicating that iledenafil has a better promoting effect on the recovery of ischemic cerebral infarction than sildenafil, and iledenafil can significantly promote the recovery of brain memory.

[0138] Example 22: Comparison of the therapeutic effects of intravenous administration of irdenafil citrate and sildenafil citrate in ischemic stroke model rats 1. Test Reagents and Drugs

[0139] [Table 7]

[0140] 2. Test Equipment

[0141] [Table 8]

[0142] 3. Information on ordering laboratory animals

[0143] [Table 9]

[0144] Feeding and Care All rats were housed at temperatures between 20.5 and 24.5°C, humidity between 40 and 75%, and a light cycle of 12 hours light and 12 hours darkness. A maximum of five rats were housed in each cage with a cage size of 48 cm x 35 cm x 20 cm. The padding used under the cage was sterilized shaving padding, which was changed twice a week. During the experiment, all experimental rats were fed ad libitum, and padding and drinking water were sterilized under autoclaving and changed twice a week. Each cage had a clear and detailed corresponding abel.

[0145] 4. Test Method Model preparation On the day of the experiment, rats were anesthetized with isoflurane gas and placed in a supine position for fixation. The skin was incised along the midline of the neck to expose the right common carotid artery. The nerves and fascia surrounding the vessels from the common carotid artery branch to the base of the skull were carefully removed, and the external and internal carotid arteries were isolated consecutively. An MCAO suture was inserted from the free end of the external carotid artery, and a nylon suture was introduced from the distal end of the external carotid artery to the internal carotid artery. This was inserted into the circle of Willis of the middle cerebral artery to effectively block the middle cerebral artery. The length of the inserted suture was 18-20 mm away from the branch of the common carotid artery. The free end of the external carotid artery was then ligated along the intravascular suture to prevent bleeding. The subcutaneous fascia and skin were sutured in layers, and penicillin was added dropwise locally to prevent infection. For the sham group, only the internal carotid artery was isolated. Two hours after the initiation of MCAO, the suture was carefully removed from the lumen of the internal carotid artery to allow reperfusion of the internal carotid artery. The animals were kept in their cages.

[0146] Two hours after embolization and then reperfusion, the degree of neurological damage in the animals was scored using a blinded method according to the scoring criteria in the attached table. Those with significant neurological impairment (≧8 points) were considered as successful modeling.

[0147] Grouping and administration The animals that were successfully modeled were randomly divided into three groups, namely, model control group, AD group (sildenafil citrate group) of 10mg / kg compound 1, and XD group (sildenafil citrate group) of 10mg / kg compound 2, based on their scores, with 10 animals in each group. Immediate administration 2 hours after cerebral ischemia and reperfusion, the test drug was intravenously administered once a day for 7 consecutive days. The end point of the experiment is 14 days after administration, and the dosage is detailed in the table below.

[0148] [Table 10]

[0149] Mode of administration In this study, the drug was administered intravenously once daily for 7 consecutive days at a dosage of 10 mg / kg in a volume of 5 mL / kg.

[0150] Compound AD: formulated as follows: dosage 10 mg / kg, dose volume 5 ml / kg, i.e., 10 mg / 5 ml = 2 mg / ml; use immediately and discard any remaining material; Compound XD: formulated as a dosage of 10 mg / kg, dosing volume of 5 ml / kg, i.e. 10 mg / 5 ml = 2 mg / ml; prepare and use as needed and discard any remaining material.

[0151] Detection indicators Neurological function score Scoring is done before treatment, 3 days after treatment, 7 days after treatment, and 14 days after treatment.

[0152] Determination of the extent of cerebral infarction At the end of the experiment, the rat brain tissues were collected by exsanguination, frozen in a -20°C freezer, and then sliced ​​at a thickness of 2 mm per slice. The brain tissue slices were placed in a 2% red tetrazolium (TTC) solution and incubated at 37°C for 5 min. Infarcted tissue appeared white, whereas non-infarcted tissue appeared red. The area of ​​cerebral infarction was measured using Image J software, and the percentage of infarcted area to total brain area was calculated.

[0153] Data analysis method The measurement data,

[0154]

number

[0155] 5. Test Results Effects on behavioral scores in rats Compared with the model control group, the AD 10 mg / kg group showed significantly improved behavioral scores (P<0.05) 7 and 14 days after administration. The XD 10 mg / kg group showed a tendency to improvement, but no statistical difference was observed. The results are shown in Table 4.

[0156] [Table 11]

[0157] Effect on the size of cerebral infarction in rats Compared with the model control group, the improvement rate of cerebral infarction area in the AD 10 mg / kg group was 29.6% (P<0.05) 14 days after administration. The results are shown in Table 5.

[0158] [Table 12]

[0159] The experimental results were unexpected: sildenafil citrate had a statistically significant therapeutic effect in stroke model rats, significantly improved their neurological function and reduced the extent of cerebral infarction.However, sildenafil citrate did not have a statistically significant therapeutic effect in stroke model rats, and could not significantly improve neurological function or significantly reduce the extent of cerebral infarction in stroke model rats.

[0160] Example 23: Comparative study on repair of nerve damage in MCAO rats by oral administration of Irdenafil Citrate, Yukinafil Citrate, and Tadalafil 1. Purpose of the experiment The restorative effects of three different compounds (irdenafil citrate, yukinafil citrate, and tadalafil) on nerve injury in MCAO rats were evaluated.

[0161] 2. Experimental Materials a) Experimental Drugs Irdenafil citrate was over 99% pure and homemade. Physical and chemical properties: White powder, solid, slightly soluble in water, soluble in DMF or DMSO. Storage method: Closed at room temperature. Shelf life: 2 years.

[0162] Yukinafil citrate was more than 99% pure and homemade. Physical and chemical properties: White powder, solid, soluble in water, soluble in DMF or DMSO, Storage method: Closed at room temperature, Shelf life: 2 years.

[0163] Tadalafil was homemade with a purity of over 99%. Physical and chemical properties: White powder, solid, insoluble in water, soluble in DMF or DMSO. Storage method: Closed at room temperature. Shelf life: 2 years.

[0164] b) Experimental animals SD rats (210-230 g, male, purchased from Sibeifu (Beijing) Biotechnology). After purchase, the rats were properly raised in the laboratory for 1-2 weeks and then followed for the subsequent experiments.

[0165] 3. Experimental methods and processes a) Drug Preparation Preparation of Irdenafil Citrate: 1600mg of Irdenafil Citrate drug was accurately weighed and dissolved in 800ml of pure water to prepare a 2mg / ml drug solution, which was kept refrigerated at 4℃ for later use.

[0166] Preparation of yukinafil citrate: 1600mg of yukinafil citrate drug was accurately weighed and dissolved in 800ml of pure water to prepare a 2mg / ml drug suspension solution, which was refrigerated and stored at 4℃ for later use.

[0167] Preparation of Tadalafil: 1600 mg of tadalafil drug is accurately weighed and dissolved in 800 ml of 5% CMC Na to prepare a 2 mg / ml drug suspension solution, which is prepared extemporaneously if necessary.

[0168] b) Route of administration, dosage, and frequency of administration; Route of administration: oral gavage; Dosage: 8 mg / kg body weight, twice daily; Dosage frequency: twice daily by gavage in the morning and evening (administered immediately after modeling).

[0169] c) Generation of the MCAO model A rat model of middle cerebral artery ischemia / reperfusion (MCAO / R) was created using the suture-occlusion technique.

[0170] Two hours after embolization and then reperfusion, the degree of neurological damage in the animals was scored using a blinded method according to the scoring criteria in the attached table. Those with significant neurological impairment (≧8 points) were considered as successful modeling.

[0171] d) Experimental grouping The rats that were successfully modeled were randomly divided into four groups based on their scores, with an average of 20 rats in each group, which were labeled as MCAO model group (referred to as model group), aldenafil treatment group 1, yukinafil treatment group 2, and tadalafil treatment group 3, respectively.

[0172] 1) MCAO model group: cerebral ischemia-reperfusion group; 2) Treatment group 1: MCAO model + alder citrate drug treatment group; 3) Treatment group 2: MCAO model + yukinafil citrate drug treatment group; 4) Treatment group 3: MCAO model + tadalafil drug treatment group;

[0173] e) Experimental Measurements Neurological function scores: Assessments were performed before treatment, and 3, 7, and 14 days after treatment.

[0174] Determination of the extent of cerebral infarction At the end of the experiment, the rat brain tissues were collected by exsanguination, frozen in a -20°C freezer, and then sliced ​​at a thickness of 2 mm per slice. The brain tissue slices were placed in a 2% red tetrazolium (TTC) solution and incubated at 37°C for 5 min. Infarcted tissue appeared white, whereas non-infarcted tissue appeared red. The area of ​​cerebral infarction was measured using Image J software, and the percentage of infarcted area to total brain area was calculated.

[0175] f) Data analysis method The measurement data,

[0176]

number

[0177] 4. Test Results -Effects on rat behavior scores Compared with the model control group, the irdenafil group showed significant improvement in behavioral scores after 3, 7 and 14 days of administration (P<0.05). There was a tendency of improvement between the yukinafil group and the tadalafil group, but no statistically significant difference was observed. After 14 days of administration, the group treated with irdenafil was more effective than the groups treated with yukinafil and tadalafil, with significant differences (P=0.037 between the irdenafil and sildenafil groups, and P=0.026 between the irdenafil and tadalafil groups).

[0178] Effects on the extent of cerebral infarction in rats Compared with the model control group, the improvement rate of cerebral infarction area in the aldenafil group after 14 days was 31.5% (P<0.05). The results are shown in Table 6.

[0179] [Table 13]

[0180] Notes: 1. Compared with the model control group, the P value of the aldenafil group was 0.0002, *P<0.05, indicating that the aldenafil group could significantly improve the extent of cerebral infarction. 2. Compared with the model group, the yukinafil group and the tadalafil group had P>0.05, showing a tendency to improve the extent of cerebral infarction between the yukinafil group and the tadalafil group, but no significant statistical difference was observed. 3. Compared with the group treated with yukinafil, the P value of the group treated with irdenafil was 0.035 with P<0.05, indicating that irdenafil was also significantly more effective than yukinafil. 4. Compared with the tadalafil group, the P value of the irdenafil group was 0.048 and P<0.05, indicating that irdenafil was also significantly more effective than tadalafil.

[0181] Example 24: Study on the efficacy of injection of different doses of aldenafil phosphate in MCAO rats 1. Experimental Design Animal selection: Healthy SD rats were used as experimental animals. Ten rats were used in each group to estimate the effect of individual animal variation on the results. The experimental process strictly followed the requirements of the protocol to ensure animal welfare. Dosage and route of administration: The low dose of 2.5mg / kg, the medium dose of 5mg / kg, and the high dose of 10mg / kg of the test drug were administered using irdenafil phosphate (code ADLS1026). Two hours after cerebral ischemia-reperfusion, the drug was immediately injected into the tail vein for seven consecutive days.

[0182] 2. Test materials Test substance: Aildenafil phosphate; Batch number: 20220908.

[0183] [Table 14]

[0184] [Table 15]

[0185] [Table 16]

[0186] All rats were housed at temperatures between 20.5 and 24.5°C, humidity between 40 and 75%, and a light cycle of 12 hours light and 12 hours darkness. A maximum of five rats could be housed in each breeding cage with a cage size of 48 cm x 35 cm x 20 cm. The padding used under the cage was sterilized shaving padding, which was changed twice a week. During the experiment, all experimental rats were fed ad libitum, and padding and drinking water were sterilized under autoclave and changed twice a week.

[0187] 3. Test Method Model preparation On the day of the experiment, rats were anesthetized with isoflurane gas and fixed in a supine position. The skin was incised along the midline of the neck to expose the right common carotid artery. The nerves and fascia surrounding the vessels from the common carotid artery branch to the base of the skull were carefully removed, and the external and internal carotid arteries were separated in succession. An MCAO suture (250-280 g) was inserted from the free end of the external carotid artery, and a nylon suture was introduced from the distal end of the external carotid artery to the internal carotid artery. This was inserted into the middle cerebral artery at the circle of Willis to effectively block the middle cerebral artery. The length of the inserted suture was 18-20 mm away from the branch of the common carotid artery. The free end of the external carotid artery was then ligated along the intraluminal suture to prevent bleeding. The subcutaneous fascia and skin were sutured in layers, and penicillin was added locally in drops to prevent infection. In the sham group, only the internal carotid artery was isolated. Two hours after the start of MCAO, the suture was carefully removed from the lumen of the internal carotid artery to allow reperfusion of the internal carotid artery. The animals were kept in a cage.

[0188] Grouping and administration Successfully modeled rats with neurological function scores of 8-12 were randomly divided into four groups, with 7 rats in each group, based on the scores: model control group, low dose 2.5 mg / kg group of test drug, medium dose 5 mg / kg group of test drug, and high dose 10 mg / kg group of test drug. Test drug groups were administered with iledenafil phosphate (code ADLS1026), whereas model control group was administered with an equal volume of solvent. Immediately after 2 hours of cerebral ischemia-reperfusion, the drug was administered via tail vein injection for 7 consecutive days. The experimental endpoint is 14 days after the first administration. See Table 7 for details.

[0189] [Table 17]

[0190] Detection indicators (1) Balance beam and forelimb placement detection The balance beam and forelimb placing tests were performed 7 and 14 days after treatment, respectively.

[0191] (2) Stroke extent (TTC) After 14 days of drug treatment, rats were anesthetized with isoflurane gas to collect blood and euthanized by cervical dislocation. Brain tissue was taken and placed in a -20°C freezer for freezing, and sliced ​​from anterior to posterior, with each slice having a thickness of 2 mm. Brain tissue slices were incubated in 2% red tetrazolium (TTC) solution at 37°C for 5 min. Infarcted tissue appears white, whereas non-infarcted tissue appears red. Using Image J software, the area of ​​cerebral infarction was measured, and the percentage of infarcted area to total brain area was calculated.

[0192] (3) Data analysis method For analysis, the quantitative data were processed using the DPS data processing system of Zhejiang University.

[0193]

number

[0194] 4. Test Results Balance beam and forelimb placing tests In the rat balance beam test, the ischemic stroke model group showed significant neurological symptoms in the paralyzed limbs, such as sideways gait, falling during walking, etc. Compared with the model control group, the ADLS1026 medium and high dose groups (5 mg / kg, 10 mg / kg) significantly improved the walking ability of rats in the balance beam 14 days after treatment, as shown in Table 8 (P<0.05).

[0195] In the rat forelimb placement test, the ischemic stroke model group showed significant impairment in placing the paralyzed limb, such as no lifting or less lifting.Compared with the model control group, the ADLS1026 medium and high dose groups (5mg / kg, 10mg / kg) improved the rats' forelimb placement rate after 14 days of treatment (P<0.05).The results are shown in Table 9.

[0196] [Table 18]

[0197] [Table 19]

[0198] Effects on the extent of cerebral infarction in rats The ischemic stroke model rats showed significant cerebral infarction. Compared with the model control group, different dose groups of ADLS1026 can improve the extent of cerebral infarction in the model rats to various degrees. After 14 days of administration, the improvement rates of the low (2.5 mg / kg), medium (5 mg / kg), and high (10 mg / kg) dose groups were 22.6% (P>0.05), 46.5% (P<0.05), and 43.4% (P<0.05), respectively. The results are shown in Table 10 and Figure 12.

[0199] [Table 20]

Claims

1. 2. Use of a compound of formula (I), a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition containing same, in the preparation of a medicament for the treatment or prevention of a human disease caused by cerebral ischemia. 【Chemistry 1】

2. The use according to claim 1, characterized by the use of irdenafil or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition containing same, in the preparation of a drug for the treatment or prevention of human focal ischemic cerebral infarction, human ischemic stroke, human focal cerebral ischemic memory disorder, and senile dementia, energy metabolic depletion of human global cerebral ischemia, or human cerebral ischemic neurological symptoms caused by brain trauma.

3. 2. Use according to claim 1, characterized in that the pharma- ceutically acceptable salt of irdenafil is a citrate, sulfate, hydrochloride, phosphate, tartrate or hemi-tartrate, nicotinate, lactate, gluconate, maleate or aspartate, preferably a citrate, sulfate, hydrochloride, phosphate, tartrate or hemi-tartrate.

4. 4. Use according to claim 3, characterized in that the tartrate or hemi-tartrate of airdenafil is D-tartrate or hemi-D-tartrate, L-tartrate or hemi-L-tartrate, DL-tartrate or hemi-DL-tartrate, or meso-tartrate or hemi-meso-tartrate, preferably airdenafil D-tartrate or hemi-D-tartrate, or airdenafil L-tartrate or hemi-L-tartrate.

5. 2. The use according to claim 1, characterized in that the pharmaceutical composition comprising irdenafil or a pharma- ceutically acceptable salt thereof is an oral or injectable preparation, preferably a tablet, an oral liquid or an injectable liquid.

6. The use according to claim 5, characterized in that the effective dosage of the compound used in humans is 0.1-20 mg / kg / day, administered once or multiple times per day, preferably the oral dosage used in humans is 0.2 mg / kg / day-10 mg / kg / day and the injection dosage used in humans is 0.1 mg / kg / day-5 mg / kg / day.

7. 2. The pharma- ceutically acceptable salt of airdenafil according to claim 1, characterized in that the pharma- ceutically acceptable salt of airdenafil is airdenafil phosphate or airdenafil tartrate.

8. A pharma- ceutically acceptable salt of airdenafil according to claim 7, characterized in that the airdenafil tartrate is D-tartrate, L-tartrate, DL-tartrate or meso-tartrate, preferably airdenafil D-tartrate or airdenafil L-tartrate.

9. A process for preparing the compound according to any one of claims 1 to 8, comprising the cyclization of 4-[2-ethoxy-5-(cis-3,5-dimethylpiperazine-1-sulfonyl)benzamido]-1-methyl-3-n-propylpyrazole-5-formamide to synthesize airdenafil, characterized in that the base catalyst is sodium tert-butoxide.

Citation Information

Patent Citations

  • New applications of aildenafil and salts thereof

    CN103417543A

  • Novel compounds for treating impotence

    JP2005500381A

  • Novel uses for pde5 inhibitors

    JP2007526285A

  • Pyrrolo- and pyrazolo-pyrimidine compounds and methods of their use

    JP2009532502A

  • Composition for inhibiting apoptosis of nerve cells containing a phosphodiesterase type 5 inhibitor

    JP2016502561A